Clinical Trials
4 trialsNCT03841617 2026-06-03
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed